Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Frequently asked questions
What sector does TVRD (TVRD) operate in?
TVRD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is TVRD (TVRD) current stock price?
As of the latest data, TVRD stock price is $0.84, with a previous close of $0.94. TVRD lost -$0.10 in the last trading session, representing a -10.43% loss.
What is TVRD (TVRD) current market capitalization?
TVRD market cap is approximately 11.23 million.
What is TVRD (TVRD) Earnings Per Share (EPS)?
The trailing EPS is -$2.87, and the forward EPS is -$2.24.
What is TVRD (TVRD) EBITDA?
TVRD EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.61 million.
Does TVRD (TVRD) pay dividends?
No. TVRD does not pay a dividend.
When is TVRD (TVRD) next earnings report?
TVRD is expected to release its next earnings report on September 30, 2026.
What is TVRD (TVRD) beta (volatility) score?
TVRD has a beta of 1.554, suggesting it is more volatile than the market.
